Please login to the form below

Not currently logged in
Email:
Password:

bladder cancer

This page shows the latest bladder cancer news and features for those working in and with pharma, biotech and healthcare.

Another Tecentriq win for Roche as Avastin combo boosts survival

Another Tecentriq win for Roche as Avastin combo boosts survival

Roche has posted its second piece of positive news for Tecentriq in first-line lung cancer in a matter of days, with the drug prolonging survival when paired with Avastin and ... Tecentriq is currently approved for previously-treated NSCLC patients and

Latest news

  • NICE says OK to Keytruda for bladder cancer via the CDF NICE says OK to Keytruda for bladder cancer via the CDF

    Becomes the first immunotherapy recommended for UC after chemotherapy. Certain bladder cancer patients in England will be able to get access to Merck Sharp and Dohme’s (MSD) blockbuster Keytruda (pembrolizumab) ... Professor Thomas Powles, director of

  • BMS gets OK for monthly Opdivo dosing BMS gets OK for monthly Opdivo dosing

    cancer. It is competing in the marketplace with two other PD-1 inhibitors - Merck &Co/MSD’s Keytruda (pembrolizumab) and Roche’s Tecentriq (atezolizumab) - as well as PD-L1 inhibitors Imfinzi ... The new monthly injection can be used in a range of

  • AZ’s Imfinzi paired with Bavarian Nordic’s CV301 vaccine AZ’s Imfinzi paired with Bavarian Nordic’s CV301 vaccine

    A second phase will consist of two parallel trials with around 26 patients apiece in the two cancer indications. ... targeting drug Tecentriq (atezolizumab) in bladder cancer.

  • AZ bags key lung cancer approval for Imfinzi AZ bags key lung cancer approval for Imfinzi

    Before now Imfinzi was only approved for bladder cancer - where it has to compete head-to-head with other checkpoint inhibitors including Bristol-Myers Squibb’s Opdivo (nivolumab) and Merck ... AZ is also expecting read-outs from The KESTREL and EAGLE

  • Merck/Pfizer’s cancer immunotherapy latecomer hits a snag Merck/Pfizer’s cancer immunotherapy latecomer hits a snag

    Fourth-to-market in the PD-1/PD-L1 checkpoint inhibitor category, Bavencio (avelumab) is already approved for skin cancer Merkel cell carcinoma and bladder cancer, but hopes of extending its ... For now, it faces a tough marketing battle in bladder

More from news
Approximately 19 fully matching, plus 91 partially matching documents found.

Latest Intelligence

  • Accelerating innovation Accelerating innovation

    Also on Ipsen’s radar are opportunities in pancreatic cancer, where it’s keen to maintain the momentum gained from Merrimack’s Onivyde. ... We try to [focus on] pancreas, liver and bladder cancer, where there are very few opportunities for patients

  • Deal Watch October 2015 Deal Watch October 2015

    Immunomic Therapeutics will retain the rights to its LAMP-vax platform for other applications, including cancer immunotherapy. ... MCNA for non-muscle invasive bladder cancer (BLA filed). Licence. 137. Proteros biostructures/ Merck &Co.

  • Interview: Trevor Smith, Takeda Interview: Trevor Smith, Takeda

    There's prostate cancer drug orteronel (TAK-700) and vedolizumab for Crohn's disease and ulcerative colitis, and then the atypical antipsychotic lurasidone. ... drug and the risk of bladder cancer.

  • Country report: The healthcare market in Japan Country report: The healthcare market in Japan

    The largest therapeutic category is Renin-angiotensin system agents (antihypertensive), followed by anti-neoplastics (cancer drugs). ... bladder cancer.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics